Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal serogroups A, C, Y, W tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent vaccine containing **Neisseria meningitidis** capsular polysaccharides from serogroups A, C, W, and Y, each conjugated to tetanus toxoid (TT) as the carrier protein. It is designed to induce protective antibodies against these serogroups and prevent invasive meningococcal disease, including meningococcal meningitis and meningococcemia. It does not protect against serogroup B. The vaccine is administered as a ready-to-use solution without preservatives or adjuvants. Developed to provide broad coverage for meningococcal disease, it is indicated for individuals 2 years and older. The mechanism of action involves the humoral immune response, with polysaccharide antigens presented in a protein-conjugated form to stimulate robust, long-lasting immunity through T-cell dependent pathways[1][2][3][4][5].
- Brand names
- MenQuadfi
- Other names
- quadrivalent meningococcal conjugate vaccine tetanus toxoid
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal serogroups A, C, Y, W tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal serogroups A, C, Y, W tetanus toxoid conjugate vaccine.